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Abstract
Background: The incidence of breast cancer (BC) in Arab women is lower compared to the incidence
in the Jewish population in Israel; still, it is the most common malignancy among Arab women. There is a
steep rise in breast cancer incidence in the Arab population in Israel over the last 10 years that can be
attributed to life style changes. But, the younger age of BC onset in Arab women compared with that of
the Jewish population is suggestive of a genetic component in BC occurrence in that population.
Methods: We studied the family history of 31 women of Palestinian Arab (PA) origin affected with breast
(n = 28), ovarian (n = 3) cancer. We used denaturing high performance liquid chromatography (DHPLC)
to screen for mutations of BRCA1/2 in 4 women with a personal and family history highly suggestive of
genetic predisposition.
Results: A novel BRCA1 mutation, E1373X in exon 12, was found in a patient affected with ovarian
cancer. Four of her family members, 3 BC patients and a healthy individual were consequently also found
to carry this mutation. Of the other 27 patients, which were screened for this specific mutation none was
found to carry it.
Conclusion: We found a novel BRCA1 mutation in a family of PA origin with a history highly compatible
with BRCA1 phenotype. This mutation was not found in additional 30 PA women affected with BC or OC.
Therefore full BRCA1/2 screening should be offered to patients with characteristic family history. The
significance of the novel BRCA1 mutation we identified should be studied in larger population. However,
it is likely that the E1373X mutation is not a founder frequent mutation in the PA population.
Published: 18 January 2007
BMC Cancer 2007, 7:14 doi:10.1186/1471-2407-7-14
Received: 16 October 2006
Accepted: 18 January 2007
This article is available from: http://www.biomedcentral.com/1471-2407/7/14
© 2007 Kadouri et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.BMC Cancer 2007, 7:14 http://www.biomedcentral.com/1471-2407/7/14
Page 2 of 7
(page number not for citation purposes)
Background
Breast cancer (BC) is a leading cause of cancer morbidity
and mortality among Israeli women regardless of their
ethnic origin. Although the incidence of BC is lower in the
Arab (PA) compared with the Jewish population in Israel,
it is continuously increasing during the last decades [1]. In
our previous study conducted on a series of 312 women,
we found significantly younger age at onset and advanced
stage at presentation among Palestinian Arab (PA)
women compared with Israeli Jews [2]. Similar results
were reported for other Arab countries in the Middle East
[3,4]. These characteristics of BC in the Arab population
raise the need for development of screening programs for
early detection and the defining of high risk individuals in
that population.
Young age at diagnosis in a cohort of BC patients may be
associated with a genetic predisposition such as the pres-
ence of a BRCA1 or BRCA2 mutations in Ashkenazi
women [5]. A recent report of the Israel Center of Disease
Control showed a higher risk of BC in Arab women with
family history of BC in Israel [6].
The role of BRCA1/2 mutations in the Arab population
was understudied; therefore the genetic component and
the contribution of the BRCA1/2 genes to BC or ovarian
cancer (OC) in that population are unknown. Only 5–
10% of newly diagnosed BC patients and about 5% of OC
cases are attributable to high penetrant breast cancer pre-
disposing genes [7]. BRCA1 and BRCA2 can be identified
in about half of the breast cancer patients with positive
family history [7]. Higher frequency of BRCA1 and BRCA2
germ-line mutations were found in Ashkenazi Jewish
breast and ovarian cancer patients regardless of family his-
tory [5]. Up to now, only two BRCA mutations, a novel
BRCA2 mutation (2482delGACT) and a BRCA1 mutation
(Arg841Trp) were reported in Arab BC patients from
Saudi-Arabia [8].
The present study was conducted on a population of 31
PA women who were treated in our institution for BC or
OC and referred to the onco-genetic clinic. The majority of
them were diagnosed below of age 50 years and/or pre-
sented with a family history of BC. Full sequencing was
done in 4 of them with a personal and family history sug-
gestive of a genetic predisposition. After identifying a




Thirty-one women of Palestinian origin affected with
breast (n = 28) or ovarian (n = 3) cancer were referred for
genetic counseling in the Cancer Genetic Clinic in Hadas-
sah medical center during 1995–2002. All participants
signed an informed consent approved by the institutional
ethics committee. Clinical characteristics of study popula-
tion are presented in table 1. Of 28 women affected with
BC, 12 were diagnosed before age 40, 7 at age 41–50 and
9 above age 50 years. Family history of BC was recorded
in 5 of them and additional 3 women reported a history
of 3 or more cases of BC in the family. Among 3 women
affected with OC, 2 had family history of BC. A history of
other cancers (pancreas, prostate, leukemia, lymphoma,
lung, and others) was reported in 13 families (in 4 of
them, it was in addition to BC history).
Full screening and sequencing of BRCA1 and BRCA2
genes was performed on DNA from four women with a
family history highly suggestive of genetic predisposition.
Of the 3 OC patients, one individual, who was diagnosed
at age 45 and had 3 sisters affected with BC (one of them
had bilateral BC, see family tree in figure 1), was analyzed.
In addition, of 12 young onset BC patients, 3 women with
the most suggestive combination of age at onset and fam-
ily history were chosen for screening. Therefore, 3 patients
affected at ages: 24 (with 2 first degree relatives affected
with BC); 31 (with an aunt affected with BC and other rel-
atives affected with lung and pancreatic cancer) and 38
(with 3 sisters affected with BC) were analyzed.
Genotype analysis
Genomic DNA was extracted according to standard proto-
cols for mutation analysis. DNA samples were used as a
template for PCR and DHPLC screening analysis.
Establishing DHPLC conditions
Denaturing high-pressure liquid chromatography
(DHPLC, Transgenomic, Omaha, NE, [10]) and direct
sequencing were used to screen stored leukocyte genomic
DNA for mutations within the full BRCA1 & 2 genes
sequences. Scanning for mutations or polymorphism by
DHPLC involves subjecting PCR products (unpurified) to
ion-pair reverse-phase particles. Under conditions of par-
tial heat denaturation within a linear acetonitrile gradient,
heteroduplexes that form in PCR samples having internal
sequence variation display reduced column retention
time relative to their homoduplex counterparts. The elu-
tion profiles for such samples are distinct from those hav-
ing a homozygous sequence, making the identification of
samples harboring polymorphisms or mutations a
straightforward procedure. Both upstream and down-
stream DNA sequencing were performed to characterize
the exact sequence variation of different chromatograms
detected by the screening with the DHPLC [11]. The DNA
screening was performed using a WAVE apparatus from
Transgenomic Inc. (Omaha, NE). The PCR products were
denatured at 95°C for 5 min and cooled to 65°C down a
temperature ramp of 1°C/min. The samples are kept at
4°C until 5 µl are applied to a preheated C18 reversedBMC Cancer 2007, 7:14 http://www.biomedcentral.com/1471-2407/7/14
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Table 1: clinical characteristics of study population: diagnosis, age at onset and family history.
Breast Cancer (n = 28) Ovarian Cancer (n = 3)
Age at onset (years) <40 (n = 12) 41–50 (n = 7) >50 (n = 9) 453 56 60
Family History:
BC1(n) 3 2 3 yes yes no
Other Cancers2(n) 5 4 4 yes no yes
1In 3 patients a history of 3 or more cases of BC was reported.
2Type of other cancer diagnosis in the families included: pancreas, prostate, leukemia, lymphoma, lung and others.
3Carrier of the E1373X BRCA1 mutation.
Family tree of a patient of Palestinian Arab origin (DNA no. 8) found to carry the E1373X-BRCA1 mutation Figure 1
Family tree of a patient of Palestinian Arab origin (DNA no. 8) found to carry the E1373X-BRCA1 mutation.BMC Cancer 2007, 7:14 http://www.biomedcentral.com/1471-2407/7/14
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phase column based on non-porous poly (styrene-divi-
nyl-benzene) particles (DNA-Sep Cartridge, CAT no.
450181; all DHPLC catalog numbers are Transgenomics
Inc.). DNA was eluted within a linear acetonitrile gradient
consisting of buffer A (0.1 M triethylammonium acetate
(TEAA) – CAT no. SP5890)/buffer B (0.1 M TEAA, 25%
acetonitrile – CAT no. 700001). The temperature at which
heteroduplex detection occurred was deduced from the
Transgenomic software (Wavemaker 4.1) and The Stan-
ford DHPLC melting program [12], which analyzes the
melting profile of the specific DNA fragment. Each exon
was screened for the BRCA1 (31 fragments) and BRCA2
(40 fragments). PCR products with alter chromatograms
were sequenced using ABI 310 sequencer.
The assay for the mutation E1373X in the BRCA1 gene
The mutation was tested in a multiplex PCR, using allele
specific oligonucleotide primers, 12-F: 5'-CTG CTG CCA
ATG AGA AGA AA-3'; 1373X R: 5'-CTT CAG AGA CGC
TTG TTT CAC TCG GA-3'. The E1373X mutation gener-
ated a PCR product of 120bp, the normal allele does not
yield any PCR product. A control PCR generated a 600bp
product from both the mutant and normal alleles. All
mutation analyses included positive and negative controls
for the mutation, confirmed by sequencing (fig. 2).
Results
Table 2 presents mutations and polymorphisms, which
were found among the 4 patients (DNA numbers 8–11).
A total of 16 alterations were found In the BRCA1 gene: 1-
nonsense mutation, 6 missense mutations (5 of them are
polymorphisms and one, a mutation designated M1652I,
of unknown importance according to the BIC database
[13]), 3 IVS, 5 silent and 1 5UTR.
The BRCA1 nonsense mutation, designated E1373X is in
exon 12. It was found in a patient diagnosed with ovarian
cancer at age 45. The family tree is presented in figure 1.
Following the detection of the mutation additional 4 fam-
ily members were tested for this mutation, 3 were found
to be carriers of this mutation. Two women affected with
BC (one at age 40 and the other at age 50, one of them had
bilateral BC) and one was a healthy individual aged 32.
Screening of the other 30 patients for the E1373X-BRCA1
mutation revealed no other carrier of this mutation.
The missense mutation in exon 16, M1652I, with
unknown importance according to the BIC database [13]
was found in a women diagnosed at age 31 with a family
history of an aunt with BC and a mother affected with
lung cancer. The mutation could not be screened in addi-
tional family members to further elucidate the role of this
mutation.
No disease causing mutation was found in the BRCA2
gene. Seven DNA alterations were found: 2 IVS, 3 silent
mutations, 1 5UTR and 1 missense mutation (categorized
in the BIC database [13] as polymorphism).
Discussion
In the present study, which follows a previous clinical and
pathological analysis of a cohort of BC patients of PA ori-
gin [2], we focus on identifying BRCA1/2 mutations
among BC/OC PA patients with suggestive family history.
In 4 patients screened for BRCA1/2 mutations, we have
found one nonsense BRCA1 mutation, a G to T base
change located at base 4236, which translates to a stop
codon at codon 1373. The family history is a typical for
BRCA1 carrier family, with women affected with BC and
OC, young age at onset of BC and a history of bilateral BC
[5]. A history of male BC, which was recorded in the fam-
ily, is a typical feature of BRCA2, although BRCA1 carrier
status was associated with male BC as well [14]. The other
3 women, in whom no mutation was found were diag-
nosed with BC at young age and had a family history of
BC.
Recently we reported [2] a clinico-pathological analysis of
three ethnic groups in a cohort of 312 women affected
with BC. Survival, age and stage at diagnosis were com-
pared between Ashkenazi Jews (AJ), Sephardic Jews (SJ)
and Palestinian Arabs (PA) in Jerusalem. The mean age at
diagnosis was 51.5 years for the PA group and 55.9 years
for the AJ group (p < 0.03). Eleven percent of the PA
patients were under the age of 35 as compared to only 5%
of the two Jewish (Ashkenazi and non-Ashkenazi) study
groups. A study from the Kingdom of Saudi Arabia [3]
reported an overall low incidence of breast cancer in the
population studied. However, 78% of the women were
diagnosed before the age of 50 years and 79% were pre-
menopausal at diagnosis. Another study reported by the
same group [4] showed young age and advanced stage at
presentation of breast cancer patients with 64% being
younger than 50 years at the time of diagnosis and 62%
being premenopausal. These data suggests role for a
genetic predisposition in addition to environmental and
hormonal risk factors in BC development in this popula-
tion. The young onset of BC among PA women is also
attributed to the revolution in life style factors such as the
increased utilization of hormones in form of contracep-
tives or fertility treatments that leads to steep rise in the
incidence of BC in that population. In that case, the
increase in BC incidence is first manifested in the younger
age group at risk and later as the cohort gets older it will
gain its accurate distribution by age. Still, genetic predis-
position may be modified by the rapid change in life style
and hormonal factors in this population. Therefore, this
understudied population can provide important data
regarding gene-environment interactions in well designedBMC Cancer 2007, 7:14 http://www.biomedcentral.com/1471-2407/7/14
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A gel picture pf PCR product of E1373X mutation analysis Figure 2
A gel picture pf PCR product of E1373X mutation analysis. The E1373X mutation generated a PCR product of 120 bp (marked 
by an arrow) and the normal allele does not yield any product. A control PCR generated a 600 bp product from both the 
mutant and normal alleles.
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studies. Genetic studies may also aid in population educa-
tion and compliance with early detection screening pro-
grams.
In addition to full BRCA1/2 sequencing of 4 DNA from
the above mentioned patients we also screened 27 DNA
samples from affected PA individuals for this BRCA1
mutation (E1373X). We did not find additional carrier in
this group. Only one previous report of a BRCA2 muta-
tion (2482delGACT) found in a BC patient from PA
descent was published [8]. Zlotogora et al [15,16] studied
and reviewed the inheritance of genetic disorders in the
PA population. The Arab population is genetically hetero-
geneous; therefore the distribution of genetic disorders in
this population is not uniform. Most of the PA population
in Israel and in the Palestinian Authority lives in villages/
tribes that were founded by few individuals less than 10
generations ago and often includes less than 10,000
inhabitants. Consanguineous marriages are frequent in
this population, therefore, each of the villages may be
considered as a small isolated community [16]. Indeed,
there are diseases that are prevalent in some villages and
rare or absent in others, while diseases that are relatively
frequent among Muslim Arabs are more homogenously
prevalent in the PA population in Israel as well [16].
Therefore, our study may result in various private muta-
tions responsible for morbidity in relatively small com-
munities.
Conclusion
We attempted to delineate the genetic component of BC/
OC among the PA population. However, only full
sequencing of the BRCA1/2 genes and study of the partic-
ular BRCA1 mutation that we identified in a larger popu-
lation may provide complete picture regarding the role of
BRCA1/2 mutations in the studied population. Based on
our study full BRCA1/2 screening should be offered to
families with a history highly suggestive of genetic predis-
position. It is likely that the E1373X mutation is not a
founder frequent mutation in the PA population.
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cancer (DNA no. 8) identified using DHLPC and sequencing.
NO. OF DNA Exon, Gene NT Codon Base Cange Mutation Type Designation AA Cange
8 12 BRCA1 4236 1373 G to T Nonsense E1373X E to STOP
11 16 BRCA1 5075 1652 G to A Missense-UV M1652I M to I
9 1BRCA1 -233 from 5UTR g to a IVS -233 from 5UTR g/a
8 IVS6 BRCA1 IVS6 +62 t to c IVS IVS6 -62 t/c IVS
9,10,11 IVS7 BRCA1 IVS7 -65 Del a IVS7 -65 del a IVS
9 11.3 BRCA1 1868 583 A toG K to K K583K Silent
11 11.3 BRCA1 1955 612 G to A R to R R612R Silent
9,10,11 11.4 BRCA1 2196 693 G to A D to N D693N Missense -P
9,10,11 11.4 BRCA1 3001 694 C to T S to S S694S Silent
9,10,11 11.5 BRCA1 2430 771 T to C L to L L771L Silent
9,10,11 11.5 BRCA1 2731 871 C to T P to L P871L Missense-P
8,9,10,11 11.7 BRCA1 3232 1038 A to G E to G E1038G Missense-P
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